Coherus BioSciences (CHRS) Given Daily Coverage Optimism Rating of 0.28

Press coverage about Coherus BioSciences (NASDAQ:CHRS) has trended positive on Friday, AlphaOne Sentiment reports. AlphaOne, a division of Accern, ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Coherus BioSciences earned a media sentiment score of 0.28 on AlphaOne’s scale. AlphaOne also assigned news coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted AlphaOne Sentiment’s analysis:

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Shares of Coherus BioSciences (NASDAQ:CHRS) traded down 1.33% on Friday, reaching $14.85. The company’s stock had a trading volume of 1,226,180 shares. The company’s market cap is $761.63 million. Coherus BioSciences has a 12-month low of $14.00 and a 12-month high of $31.98. The company’s 50 day moving average price is $20.31 and its 200 day moving average price is $23.38.

Coherus BioSciences (NASDAQ:CHRS) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($1.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.54). The firm had revenue of $0.16 million for the quarter. Coherus BioSciences had a negative return on equity of 827.65% and a negative net margin of 76.85%. Analysts forecast that Coherus BioSciences will post ($5.13) EPS for the current fiscal year.

CHRS has been the subject of several recent analyst reports. Maxim Group decreased their target price on Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Monday. Citigroup Inc. set a $38.00 target price on Coherus BioSciences and gave the stock a “buy” rating in a research note on Wednesday, May 17th. Credit Suisse Group reaffirmed a “buy” rating and set a $38.00 target price on shares of Coherus BioSciences in a research note on Friday, April 21st. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Coherus BioSciences in a research note on Monday. Finally, Zacks Investment Research cut Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Thursday, February 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $37.11.

ILLEGAL ACTIVITY NOTICE: This article was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at

In related news, insider Alan C. Herman sold 11,333 shares of the company’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $20.73, for a total value of $234,933.09. Following the sale, the insider now owns 90,452 shares in the company, valued at approximately $1,875,069.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.88% of the company’s stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.